Kenneth C. Frazier is Chairman of the Board and Chief Executive Officer of Merck & Co., Inc.
Under Mr. Frazier’s leadership, Merck is delivering innovative lifesaving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders. Mr. Frazier has substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide benefit to society. He has also led the formation of philanthropic and other initiatives that build on Merck’s 125-year plus legacy.
Mr. Frazier joined the company in 1992 as Vice President, General Counsel and Secretary of the company’s joint venture with Astra AB. He became Vice President of Public Affairs in 1994, and in 1997, was also named Assistant General Counsel. In 1999, Mr. Frazier was promoted to General Counsel of Merck. From 2007 to 2010, he served as President of Global Human Health, Merck’s sales and marketing division. In 2010, Mr. Frazier became President of Merck. He was appointed CEO and a member of Merck’s Board of Directors in January 2011 and became Chairman of the Board in December 2011.
Prior to joining Merck, Mr. Frazier was a partner with the Philadelphia law firm of Drinker Biddle & Reath. He sits on the boards of PhRMA, Weill Cornell Medicine, Exxon Mobil Corporation, and Cornerstone Christian Academy in Philadelphia, PA. He also is a member of the American Academy of Arts and Sciences, The Business Council, the Council of the American Law Institute, and the American Bar Association.
Mr. Frazier received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.